World Pharma Today: 2022 biopharma trends roundtable

Scroll Down

The potential of both mRNA technologies and lipid nanoparticle (LNPs) have been highlighted throughout the COVID-19 pandemic. With the upsurge in the mRNA technologies in clinical pipelines globally, 2022 will be a year dominated by mRNA-based products.

In this commentary, Bill Vincent, Founder and Executive Chairman at Genezen, highlights mRNA technologies as the innovation disrupting the biopharmaceutical industry and discusses how LNPs could further impact drug product development in future.

Read the full article here: 2022 innovations to look out for in the pharma arena

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more